Is Gelesis Holdings, Inc. (GLS) a Buy, Sell, or Hold?
Gelesis Holdings, Inc.
NYSE:GLS
$0.1586 USD
$0 (0.0%)
- Volume
- 185.17K
- Average Volume
- 570.67K
- Market Capitalization
- $11.63M
- P/E Ratio
- -0.20
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $5.67
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.46
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Yishai Zohar |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GLS |
| CUSIP | 36850R204 |
| CIK | 0001805087 |
| Web | https://www.gelesis.com |
| Phone | 617 456 4718 |
| Currency | USD |
| Employees | 93 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -2.48 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.46 |
| Quick Ratio | 0.33 |
| Cash Ratio | 0.15 |
Sales & Book Value
| Annual Sales | $25.77M |
| Price / Sales | 0.45 |
| Cash Flow | -1.24 |
| Price / Cash Flow | -0.13 |
| Price / Book | -0.44 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.79 |
| Trailing P/E Ratio | -0.20 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $-55.78M |
| Net Margin | -216.48% |
| Pretax Margin | -214.62% |
| Return on Equity | 31.43% |
| Return on Assets | -53.99% |
Financials Score
| AltmanZ Score | -7.78 |
| Piotroski Score | 3.00 |
| Working Capital | -51.86M |
| Total Assets | 95.88M |
| Ebit | -70.15M |
| Market Cap | 11.63M |
| Total Liabilities | 114.5M |
Poll Results
About Gelesis Holdings, Inc. (NYSE:GLS) Stock
Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal conditions. Among its key offerings is PLENITY, an oral therapeutic designed for weight management that is non-stimulant and does not enter the bloodstream. The company also provides an additional product for individuals who are overweight or obese, and its robust pipeline features potential treatments for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Established in 2006, Gelesis Holdings Inc. operates from its headquarters in Boston, Massachusetts. ...
Frequently Asked Questions
-
What is the current Gelesis Holdings, Inc. (GLS) stock price?
-
Gelesis Holdings, Inc.(NYSE:GLS) stock price is $0.1586 in the last trading session. During the trading session, GLS stock reached the peak price of $5.67 while $0.012 was the lowest point it dropped to. The percentage change in GLS stock occurred in the recent session was 0.0% while the dollar amount for the price change in GLS stock was $0.
-
GLS's industry and sector of operation?
-
The NYSE listed GLS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GLS?
-
Alessandro Sannino | Co-Inventor & Lead Project Scientist
Elliot Maltz | Chief Financial Officer, Treasurer, Chief Compliance Officer & Corporation Sec.
|
|
| -
How many employees does GLS have?
-
Number of GLS employees currently stands at 93. GLS operates from 501 Boylston Street, Boston, MA 02116, US.
-
Link for GLS official website?
-
Official Website of GLS is: https://www.gelesis.com
-
How do I contact GLS?
-
GLS could be contacted at phone #617 456 4718 and can also be accessed through its website. GLS operates from 501 Boylston Street, Boston, MA 02116, US.
-
How many shares of GLS are traded daily?
-
The average number of GLS shares traded daily for last 3 months was 570.67K.
-
What is the market cap of GLS currently?
-
The market value of GLS currently stands at $11.63M with its latest stock price at $0.1586